Gannet BioChem Announces Key Leadership Appointments Following Acquisition by Ampersand Capital Partners
Slice of Manufacturing Team
Mar 17, 2025
Key Highlights:
- Nicholas Shackley appointed as Chief Executive Officer, bringing 25+ years of pharmaceutical and chemical manufacturing expertise.
- Chris Edwards named Chief Financial Officer, leveraging global finance experience from Solesis, Syneos Health, and Bristol-Myers Squibb.
- Dr. Tony Sander, a Gannet BioChem veteran, promoted to Chief Operating Officer, overseeing operations at the Huntsville, AL facility.
- Gannet BioChem to showcase industry-leading capabilities at DCAT 2025, focusing on polyethylene glycol (PEG) reagent manufacturing.
- Leadership appointments reinforce the company's commitment to innovation and biopharmaceutical advancements.
Source: PR Newswire
Quotes
“ "These leadership appointments mark an exciting new chapter for Gannet BioChem as an independent company. We are thrilled to welcome Nick and Chris to the leadership team, while continuing to collaborate with Tony in his expanded role." ”
Melanie Fan, Principal at Ampersand Capital Partners
Why This Matters:
Gannet BioChem's leadership transition underscores its strategic growth and enhanced focus on innovation in biopharmaceutical manufacturing. With Ampersand Capital Partners’ backing, the company is well-positioned to scale its PEG reagent manufacturing and solidify its global presence. The upcoming participation at DCAT 2025 further emphasizes its commitment to industry leadership and innovation.
